Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.

Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.